Study of the blood lipids levels with coronary heart disease in the races of the Uygur and the Hans in Xinjiang, China

Chinese Journal of Clinical Rehabilitation

Volumn 7, Issue 9, 2003, Pages 1408-1409

  Chu, Xinmei ^a,c   Meng, Zhu ^a   Dai, Wenying ^b   He, Bingxian ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

^b Hosp of 2nd Agric Troop Xinjiang   (China)

^c PEOPLE S HOSPITAL OF XINJIANG UYGUR AUTONOMOUS REGION   (China)

Author keywords

Blood glucose; Coronary arteriosclerosis; Lipoproteins

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; CHINA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; ETHNIC GROUP; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; RACE DIFFERENCE; RISK FACTOR; SEX DIFFERENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 2442622527     PISSN: 16715926     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease: the Framingham Study. Ann Epidemiol 1992; 2(1-2): 23-8
2. Wiersbicki AS, Mikhailidis DP. Beyond LDL-C-the importance of raising HDL-C. Curr Med Res Opin 2002; 18(1): 36-44
3. Hokanson JE. Hypertriglyceridemia and risk of coronary heart disease. Curr Cardiol Rep 2002; 4(6): 448-93
4. Clearfield MB. The national cholesterol education program adult treatment panel ill guidelines. J Am Osteopath Assoc 2003; 103(1 Suppl 1): 1-5
5. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97
6. Packard C, Nunn A, Hobbs R. Future Forum Editorial Board. High density lipoprotein: guardian of the vascular systems? Int J Clin Pract 2002; 56(10): 761-71
7. Barbagallo CM, Polizzi F, Severino M, et al. Distribution of risk factors, plasma lipid, lipoproteins and dyslipidemias in a small Mediterranean island: the Ustica Project. Nutr Metab Cardiovasc Dis 2002; 12(5): 267-74
8. Nawawi HM, Nor IM, Noor IM, et al. Current status of coronary risk factors among rural Malays in Malaysia. J Cardiovasc Risk 2002; 9(1): 17-23
9. Menotti A, Lanti M. Coronary risk factor predicting early and late coronary deaths. Heart 2003; 89(1): 19-24
10. Zoratti R. A review on ethnic differences in plasma triglycerides and high-density-lipoprotein cholesterol: is the lipid pattern the key factor for the low coronary heart disease rate in people of African origin? Eur J Epidemiol 1998; 14 (1): 9-21
11. Proudler AJ, Godsland IF, Bruce R, Seed M, Wynn V. Lipid and carbohydrate metabolic risk markers for coronary heart disese and blood pressure in health non-obese premenopausal women of different racial origins in the United Kingdom. Metabolism 1996; 45(3): 328-33
12. Lyu LC, Shieh MJ, Ordovas JM, Lichtenstein AH, Wilson PW, Schaefer EJ. Plasma lipoprotein and apolipoprotein levels in Taipei and Framinghan. Arterioscler Thromb 1993; 13(10): 1429-40
13. Knapp RG, Sutherland SE, Keil JE, Rust PF, Lackland DT. A comparison of the effects of cholesterol on CHD mortality in black and white women: twenty-eight years of follow-up in the Charleston Heart Study. J Clin Epidemiol 1992; 45(10): 1119-29
14. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in scale coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285 (13): 1711-18
15. Wilhelmsen L, Pyorala K, Wedel H, Cook T, Pedersen T, Kjekshus J. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. Eur Heart J 2001; 22(13): 1119-27
16. Barter P. Treatment of dyslipidaemia in high-risk patients: too little, too late. Int J Clin Pract Suppl 2002; (130): 15-9
17. LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002; 359(9315): 1379-87
18. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assesment project (L-ATP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160(4): 459-67
19. Gotte AM Jr. How do we achieve optimal cardiovascular risk reduction? Clin Cardiol 2001; 24(8 Suppl): III8-12
20. Stein EA. Management of dyslipidemia in the high-risk patient. Am Heart J 2002; 144(6 Suppl): 43-50